QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions. It also provides Ingenuity Variant Analysis, a cloud-based platform that interprets data from next-generation sequencing (NGS) analysis; QIAGEN Clinical Insight, an evidence-based decision support solution; CLC Genomics Workbench for the analysis and visualization of data from various NGS platforms; and GeneGlobe, a Web-based portal that enables researchers to search and select gene-and pathway-specific solutions from pre-designed and custom PCR assay kits, NGS assay panels, and other products. In addition, the company offers instrumentation systems for laboratories. Its automation platforms include QIAsymphony, a modular system; GeneReader NGS System, a sample to insight NGS solution for laboratories to deliver actionable results; QIAcube robotic workstations, which provides versatile solutions for automated sample processing; QIAxcel for nucleic acid separation; QIAgility, a benchtop instrument for PCR setup; and ESEQuant instruments that enable optical measurement for point of need molecular testing in physician practices, emergency rooms, remote areas, and other applications. It serves molecular diagnostics, applied testing, pharma, and academia customers. QIAGEN N.V. has a collaboration with Bristol-Myers Squibb to develop gene expression profiles for immuno-oncology therapies. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNYSE:QGEN
CUSIPN/A
Phone31-77-355-6600
Debt
Debt-to-Equity Ratio0.53
Current Ratio1.79
Quick Ratio1.62
Price-To-Earnings
Trailing P/E Ratio29.36
Forward P/E Ratio28.04
P/E Growth2.36
Sales & Book Value
Annual Sales$1.42 billion
Price / Sales6.00
Cash Flow$2.2905 per share
Price / Cash16.28
Book Value$11.13 per share
Price / Book3.35
Profitability
EPS (Most Recent Fiscal Year)$1.27
Net Income$40.39 million
Net Margins5.26%
Return on Equity12.22%
Return on Assets6.07%
Miscellaneous
Employees4,688
Outstanding Shares228,230,000
Market Cap$8.74 billion
Qiagen (NYSE:QGEN) Frequently Asked Questions
What is Qiagen's stock symbol?
Qiagen trades on the New York Stock Exchange (NYSE) under the ticker symbol "QGEN."
What price target have analysts set for QGEN?
9 analysts have issued 12 month price targets for Qiagen's shares. Their forecasts range from $38.00 to $40.00. On average, they anticipate Qiagen's share price to reach $38.75 in the next year. This suggests a possible upside of 3.9% from the stock's current price. View Analyst Price Targets for Qiagen.
What is the consensus analysts' recommendation for Qiagen?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Qiagen in the last year. There are currently 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Qiagen.
Who are some of Qiagen's key competitors?
Some companies that are related to Qiagen include NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), AveXis (AVXS), BIO-TECHNE (TECH), Ablynx (ABLYF), China Biologic Products (CBPO), Aerie Pharmaceuticals (AERI), argenx (ARGX), Halozyme Therapeutics (HALO), Crispr Therapeutics (CRSP), Spark Therapeutics (ONCE), Acceleron Pharma (XLRN) and Regenxbio (RGNX).
Who are Qiagen's key executives?
Qiagen's management team includes the folowing people:
- Mr. Peer Michael Schatz, CEO, MD & Member of Management Board (Age 52)
- Dr. Roland Sackers, CFO, MD & Member of Management Board (Age 49)
- Mr. Douglas Liu, Sr. VP of Global Operations
- Mr. Mark Gladwell, Sr. VP of Global Operations (Age 43)
- Mr. John Gilardi, VP of Corp. Communications & Investor Relations
Has Qiagen been receiving favorable news coverage?
Media headlines about QGEN stock have trended somewhat positive on Thursday, Accern Sentiment reports. Accern identifies negative and positive news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Qiagen earned a daily sentiment score of 0.12 on Accern's scale. They also gave press coverage about the company an impact score of 46.11 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days. View Recent Headlines for Qiagen.
How do I buy shares of Qiagen?
Shares of QGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Qiagen's stock price today?
One share of QGEN stock can currently be purchased for approximately $37.29.
How big of a company is Qiagen?
Qiagen has a market capitalization of $8.74 billion and generates $1.42 billion in revenue each year. The company earns $40.39 million in net income (profit) each year or $1.27 on an earnings per share basis. Qiagen employs 4,688 workers across the globe.
How can I contact Qiagen?
Qiagen's mailing address is HULSTERWEG 82, VENLO P7, 5912 PL. The company can be reached via phone at 31-77-355-6600 or via email at [email protected]
MarketBeat Community Rating for Qiagen (NYSE QGEN)
MarketBeat's community ratings are surveys of what our community members think about Qiagen and other stocks. Vote "Outperform" if you believe QGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
